J Clin Pharm Ther. 2021 Aug;46(4):950-956. doi: 10.1111/jcpt.13376. Epub 2021 Feb 10.

Risk comparison of beta-lactam-induced anaphylaxis: Therapeutic stratification analysis in a Vietnamese pharmacovigilance database.

Journal of clinical pharmacy and therapeutics

Khac-Dung Nguyen, Dinh-Hoa Vu, Hoang-Anh Nguyen, Van-Tu Dao, Jean-Louis Montastruc, Haleh Bagheri

PMID: 33565097 DOI: 10.1111/jcpt.13376

Abstract

WHAT IS KNOWN AND OBJECTIVE: There is limited data on the specific risks of anaphylaxis induced by beta-lactam drugs. The aim of this study was to compare the risks of reporting beta-lactam-induced anaphylaxis using the national pharmacovigilance database of Vietnam (NPDV).

METHODS: The multivariate generalised linear regression model was applied for signal generation and comparison of beta-lactams.

RESULTS: Between 2010 and 2016, there were 2,921 reports of anaphylaxis (19.93%) from 14,655 spontaneous reports of beta-lactam use in the NDPV. Anaphylaxis signal generation was also found for the subgroup J01D (cephalosporins and carbapenems) (ROR = 1.27 [1.16-1.39]) and beta-lactamase-sensitive penicillins (ROR = 1.74 [1.27-2.35]). In the third generation cephalosporin subgroup, different risks were identified for the following combinations of beta-lactams: 1) cefotaxime with cefoperazone+sulbactam; 2) cefixime/cefpodoxime/cefdinir with cefoperazone+sulbactam or ceftizoxime/cefoperazone/ceftazidime/ceftriaxone/cefotaxime. For the second generation cephalosporin subgroup, different risks were found for cefotiam compared to cefmetazole, cefaclor, cefamandole and cefuroxime.

WHAT IS NEW AND CONCLUSION: These findings identified and highlighted the different anaphylactic risks caused by various beta-lactams in the main subgroups.

© 2021 John Wiley & Sons Ltd.

Keywords: beta-lactam; developing countries; drug-induced anaphylaxis

References

1. Greenberger PA, Ditto AM. Chapter 24: anaphylaxis. Allergy Asthma Proc. 2012;33(3):80-83. - PubMed
2. Renaudin J-M, Beaudouin E, Ponvert C, Demoly P, Moneret-Vautrin D-A. Severe drug-induced anaphylaxis: analysis of 333 cases recorded by the allergy vigilance network from 2002 to 2010. Allergy. 2013;68(7):929-937. - PubMed
3. Macy E, Contreras R. Adverse reactions associated with oral and parenteral use of cephalosporins: a retrospective population-based analysis. J Allergy Clin Immunol. 2015;135(3):745-752.e5. - PubMed
4. The Uppsala Monitoring Centre. VigiBase®. Published 2018. https://www.who-umc.org/vigibase/vigibase/. Accessed July 18, 2018. - PubMed
5. Nguyen K-D, Nguyen H-A, Vu D-H, et al. Drug-induced anaphylaxis in a vietnamese pharmacovigilance database: trends and specific signals from a disproportionality analysis. Drug Saf. 2019;42(5):671-682. - PubMed
6. Ministry of Health. National Guideline of Pharmacovigilance. According to Decision 2111/QD-BYT from Ministry of Health (Vietnam). Published January 6, 2015. http://canhgiacduoc.org.vn/SiteData/3/UserFiles/HDQGCGD%20Final%2029_05_2015.pdf. Accessed December 24, 2016. - PubMed
7. WHO Collaborating Centre for International Drug Monitoring. who adverse reaction terminology (WHO-ART). Published 2012. http://www.umc-products.com/. Accessed September 18, 2017. - PubMed
8. Nguyen K-D, Nguyen P-T, Nguyen H-A, et al. Overview of pharmacovigilance system in vietnam: lessons learned in a resource-restricted country. Drug Saf. 2018;41(2):151-159. - PubMed
9. Olsson S. The role of the WHO programme on international drug monitoring in coordinating worldwide drug safety efforts. Drug Saf. 1998;19(1):1-10. - PubMed
10. van Puijenbroek EP, Egberts AC, Heerdink ER, Leufkens HG. Detecting drug-drug interactions using a database for spontaneous adverse drug reactions: an example with diuretics and non-steroidal anti-inflammatory drugs. Eur J Clin Pharmacol. 2000;56(9-10):733-738. - PubMed
11. Faillie J-L. Case-non-case studies: principles, methods, bias and interpretation. Therapie. 2019;74(2):225-232. - PubMed
12. Sampson HA, Muñoz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report-second national institute of allergy and infectious disease/food allergy and anaphylaxis network symposium. J Allergy Clin Immunol. 2006;117(2):391-397. - PubMed
13. Abe J, Umetsu R, Mataki K, et al. Analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis using the Japanese adverse drug event report database. J Pharm Health Care Sci. 2016;2(1):1-10. - PubMed
14. Moore N, Kreft-Jais C, Haramburu F, et al. Reports of hypoglycaemia associated with the use of ACE inhibitors and other drugs: a case/non-case study in the French pharmacovigilance system database. Br J Clin Pharmacol. 1997;44(5):513-518. - PubMed
15. Hauben M, Madigan D, Gerrits CM, Walsh L, Van Puijenbroek EP. The role of data mining in pharmacovigilance. Expert Opn Drug Saf. 2005;4(5):929-948. - PubMed
16. van Puijenbroek EP, Bate A, Leufkens HGM, Lindquist M, Orre R, Egberts ACG. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002;11(1):3-10. - PubMed
17. CRAN. R: The R Project for Statistical Computing. Published 2017. https://www.r-project.org/. Accessed March 11, 2017. - PubMed
18. GARP. Report of antibiotic utilization and antibiotic resistance in 15 Vietnamese hospitals in periof 2008-2009.; 2010. http://benhnhietdoi.vn/data/files/documents/Bao_cao_su_dung_khang_sinh_va_khang_khang_sinh_tai_15_benh_vien_nam_2008-2009.pdf. Accessed March 11, 2020. - PubMed
19. Doña I, Bogas G, Pérez-Sánchez N, Fernández TD, Moreno E, Torres MJ. Penicillin and cephalosporin-induced anaphylaxis: an update. Curr Treat Options Allergy. 2018;5(2):188-203. - PubMed
20. Hosohata K, Oyama S, Niinomi I, Wakabayashi T, Inada A, Iwanaga K. Comparison of safety profiles of new oral anticoagulants with warfarin using the Japanese spontaneous reporting database. Clin Drug Investig. 2019;39(7):665-670. - PubMed
21. Yang M-S, Kang DY, Seo B, et al. Incidence of cephalosporin-induced anaphylaxis and clinical efficacy of screening intradermal tests with cephalosporins: a large multicenter retrospective cohort study. Allergy. 2018;73(9):1833-1841. - PubMed
22. Zhao Y, Sun S, Li X, et al. Drug-induced anaphylaxis in China: a 10 year retrospective analysis of the Beijing Pharmacovigilance database. Int J Clin Pharm. 2018;40(5):1349-1358. - PubMed
23. Simons FER, Ardusso LRF, Bilò MB, et al. 2012 update: world allergy organization guidelines for the assessment and management of anaphylaxis. Curr Opin Allergy Clin Immunol. 2012;12(4):389-399. - PubMed
24. Simons FER, Ebisawa M, Sanchez-Borges M, et al. 2015 update of the evidence base: world allergy organization anaphylaxis guidelines. World Allergy Organ J. 2015;8:32. - PubMed
25. Klein NC, Cunha BA. Third-generation cephalosporins. Med Clin North Am. 1995;79(4):705-719. - PubMed
26. Perez-Inestrosa E, Suau R, Montañez MI, et al. Cephalosporin chemical reactivity and its immunological implications. Curr Opin Allergy Clin Immunol. 2005;5(4):323-330. - PubMed
27. EMA. Screening for adverse reactions in EudraVigilance (EMA/849944/2016). https://www.ema.europa.eu/documents/other/screening-adverse-reactions-eudravigilance_en.pdf. Published 2016. Accessed March 11, 2020. - PubMed
28. Li C, Xia J, Deng J, Jiang J. A comparison of measures of disproportionality for signal detection on adverse drug reaction spontaneous reporting database of Guangdong province in China. Pharmacoepidemiol Drug Saf. 2008;17(6):593-600. - PubMed
29. Bate A, Evans SJW. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009;18(6):427-436. - PubMed

Publication Types

• Journal Article